Hanson Wade

R&D

Partner Content

3rd Lipid Nanoparticles Development Summit Europe

Unlock LNP potential with enhanced clinical translatability at the 3rd Lipid Nanoparticles Development Summit Europe (24-26 September, Berlin, Germany), the leading dedicated LNP f

R&D

Partner Content

ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summi...

Collaborate, license, and partner to reduce risks, validate technologies, and acquire clinically ready assets

R&D

Partner Content

6th Gene Therapy Analytical Development & CMC Summit

Execute Robust Analytical & Process Development Strategies for Complex Gene Therapies

R&D

Partner Content

5th Gene Therapy for Ophthalmic Disorders Summit

Ophthalmic drug developers are unlocking the full potential of gene therapy.

R&D

Partner Content

4th Inner Ear Disorders Therapeutics Summit

2024 has started off with a bang with recent back-to-back positive results for gene therapy for rare genetic hearing disorders and major headways in otoprotective, restorative and regenerative smal

R&D

Partner Content

3rd Operationalise: Early Access Programmes Summit Europe

This annual meeting is dedicated to fostering open dialogue and sharing experiences in navigating the complex regulatory and operational landscape of Early Access Programmes.

3rd Lipid Nanoparticles Development Summit Europe

ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summi...

6th Gene Therapy Analytical Development & CMC Summit

5th Gene Therapy for Ophthalmic Disorders Summit

4th Inner Ear Disorders Therapeutics Summit

3rd Operationalise: Early Access Programmes Summit Europe

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Hanson Wade

Editor's Picks